MEMOTEXT® Corporation and MEMOTEXT LLC (USA) are privately held corporations located in Toronto, Ontario, Canada with points of presence in the United States, United Kingdom, Australia and The European Union.
MEMOTEXT has developed and successfully deployed a proprietary methodology, algorithm and communications platform to create validated improvements of greater than 30% in patient’s compliance to medication regimens.
MEMOTEXT's methodology combines evidence-based psychological and health literacy focussed medication compliance interventions with a multi-stakeholder collaborative model to create condition specific medication compliance interventions.
MEMOTEXT has designed and built the MEMOTEXT PersonoLogic® Engine (MPE), a proprietary software engine that receives methodological inputs of patient information, and then segments patients for appropriate, targeted interventions.
MEMOTEXT has validated its model with clients including randomized control trials with Johns Hopkins University (US), Microsoft HealthVault, Boots Pharmacies (UK), Biogen Idec Canada, Smith & Nephew (US and Australia), Schering Plough Canada, and other clients under which MEMOTEXT is bound by confidentiality.